Drug Discovery Industry Analysis
In this section you will find information products, including market research reports, on the following sector: Drug Discovery
previous
| Perspective: TAKE Solutions Gives Leading Pharma an Edge in Drug Serialization (IDC12623) This IDC Health Insights Perspective discusses the importance of item-level serialization and its adoption within the pharmaceutical industry. Using a leading pharmaceutical company case study as a backdrop, this document... | May 2012 | £945 |
| Janus Kinase (JAK) Inhibitors (LME00055) Competitor AnalysisThe present Competitive Intelligence Report about new developments in the pipeline of inhibitors of the janus-associated kinase (JAK) provides a competitor evaluation in the field of active R&D projects from... | May 2012 | £250 |
| CNS Drug Discoveries: Alzheimer's Disease Chapter (ESP00552) Alzheimer's disease By 2014, there will be considerable change in the Alzheimer's disease (AD) market due to generic competition, better utilisation of acetylcholinesterase inhibitors and new product launches which, for the... | Apr 2012 | £595 |
| CNS Drug Discoveries: Schizophrenia Chapter (ESP00556) Schizophrenia The antipsychotic market generated global sales of US$19.6 billion, accounting for 21% of global CNS sales in 2007. While atypical antipsychotics now account for over 80% of global sales,... | Apr 2012 | £595 |
| CNS Drug Discoveries: Depression Chapter (ESP00553) Depression Antidepressants accounted for around 21% of the total CNS drug sales in 2007, with sales of US$19.4 billion. However, we anticipate that within our forecast period to 2014, the... | Apr 2012 | £595 |
| CNS Drug Discoveries: Parkinson's Disease Chapter (ESP00555) Parkinson's disease In 2007, approximately US$3.6 billion was spent on the symptomatic treatment of Parkinson's disease (PD). Although this neurodegenerative disease affects approximately 1% of the population its prevalence increases... | Apr 2012 | £595 |
| Breast Cancer Drug Discoveries (ESP00385) What the future holdsIn 2010, almost 50% of breast cancer sales were due to three branded targeted therapies. With a large unmet clinical need, further agents are required to increase survival and delay... | Apr 2012 | £1,795 |
| Cardiovascular Drug Discoveries (ESP00589) What the Future HoldsCardiovascular disease is a global problem. In the developed world, its prevalence is linked to our increasingly unhealthy lifestyle, with risk factors including lack of exercise, overweight and obesity, and... | Apr 2012 | £1,795 |
| Advances in Vaccine Technology and Delivery (ESP00643) A comprehensive 164-page analysis of this fast-growing sector with market projections and extensive company, product and research evaluation of all major vaccine areas. A comprehensive 164-page analysis of this fast-growing... | Apr 2012 | £795 |
| Blood Cancer Drug Discoveries (ESP00481) What the Future Holds This New Strategic Report from Espicom Provides A Comprehensive Review of Current and Future Treatments for Major Blood Cancer Therapy Areas: Chronic Lymphocytic Leukaemia, Chronic Myeloid Leukaemia, Acute Myeloid Leukaemia,... | Apr 2012 | £1,295 |
| Global Inhalation Systems Market (INF01517) 2010-2014TechNavio's analysts forecast the Global Inhalation Systems market to grow at a CAGR of 6.3 percent over the period 2010-2014. One of the key factors contributing to this market growth... | Feb 2012 | £945 |
| Targeted Cancer Drugs The Launch Landscape to 2018 (ESP00780) As the cancer therapy market evolves, interest is growing in novel approaches which may supersede the current portfolio. In the short term, the market will be dominated by established therapeutic... | Feb 2012 | £1,295 |
| Dermatological Drugs (VIS00294) World Market Prospects 2012-2022Where are dermatological treatments heading? Visiongain's report shows you potential revenues to 2022, with data, forecasts and discussions. This study assesses drugs to treat human skin disorders. You discover sales predictions... | Jan 2012 | £1,699 |
| Global Intravenous (IV) Iron Drugs Market (KOA04342) 2011 EditionIron is one of the most important minerals present in the human body and performs the task of carrying oxygen throughout the body through blood, which is then further utilized... | Jan 2012 | £500 |
| Outsourcing in Drug Development (KAL00234) The Contract Research (Clinical Trial ) MarketThe cost and time of developing and bringing a drug to market is over $1.3 billion and often takes as long as 15 years, if not longer. Because of... | Jan 2012 | £2,520 |
| Mass Spectroscopy for Clinical Laboratory Analysis (TRI00132) Mass spectroscopy is a clinical laboratory analysis technique used in determining the basic composition and structure of a sample or molecule. The process involves bending a charged beam of vaporized... | Nov 2011 | £2,145 |
| GPCRs in Drug Discovery (GBI00273) Efforts to De-Orphanize Novel Gpcr Targets Are IncreasingGPCRs in Drug Discovery - Efforts to De-Orphanize Novel GPCR Targets are Increasing Summary GBI Research, the leading business intelligence provider, has released its latest research "GPCRs in Drug Discovery - Efforts... | Nov 2011 | £2,210 |
| Perspective: Drug Serialization - Moving Forward, But Slowly (IDC11935) This IDC Health Insights Perspective discusses the current state of drug serialization and pedigree adoption in the pharmaceutical industry. | Oct 2011 | £945 |
| Antibody-Drug Conjugates 2011 - real breakthrough still to come (LME00140) A Technology, Stakeholder and R&D Pipeline AnalysisProduct description This report "Antibody-Drug Conjugates 2011 - real breakthrough still to come: A Technology, Stakeholder and R&D Pipeline Analysis" published in September 2011 provides the most complete compilation of information... | Sep 2011 | £1,610 |
| China Heparin Industry Report (RIC00620) 2010-2011With richness in heparin materials and the quality of heparin API getting accredited by the international community, China has become one of the largest heparin API producers and exporters in... | Sep 2011 | £1,135 |
| Non-pharmacy OTC market in Poland 2011 (PMR00080) Development forecasts for 2011-2013Non-pharmacy OTC market in Poland 2011, Development forecasts for 2011-2013 reports on and analyses the demand, trends, retail sales rules and increasing profitability of a variety of popular products used... | Sep 2011 | £1,485 |
| Comparative Analysis of Marketed Drugs in Major Indications (GBI00243) Patent Cliff to Set off Intense Price Competition in High Volume MarketsComparative Analysis of Marketed Drugs in Major Indications - Patent Cliff to Set Off Intense Price Competition in High Volume Markets Summary GBI Research, the leading business intelligence provider, has released its... | Aug 2011 | £2,210 |
| Drug Discovery Outsourcing (VIS00306) World Market 2011-2021How will the drug discovery outsourcing market develop this decade? Our new report shows you potential revenues to 2021, discussing opportunities and prospects. Assess the activities shaping drug discovery outsourcing... | Jul 2011 | £1,499 |
| The Pain Market Outlook to 2016 (RBI00595) HealthcareIntroduction The heterogeneity of pain necessitates a wide range of analgesics with different modes of action and delivery methods. As such, many different classes of drugs co-exist in the pain market.... | Jul 2011 | £2,420 |
| Opportunities and Key Players in Medical Nutrition (RBI00598) HealthcareIntroduction A small number of products for specific diseases have been introduced over the years, but companies have only recently started to focus on the specific nutritional requirements of patients with... | Jul 2011 | £3,025 |
